Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Pharmacol. Dec 9, 2014; 3(4): 193-198
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.193
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.193
Perspective of antiviral therapeutics for hepatitis C after liver transplantation
Cheng-Maw Ho, Rey-Heng Hu, Po-Huang Lee, Department of Surgery, National Taiwan University Hospital, Taipei 100, Taiwan
Author contributions: Ho CM conceived of the study and wrote the manuscript; Hu RH and Lee PH helped revise the manuscript.
Correspondence to: Cheng-Maw Ho, MD, Department of Surgery, National Taiwan University Hospital, 7 Chun-Shan S Rd, Taipei 100, Taiwan. miningho@ntu.edu.tw
Telephone: +886-2-23123456 Fax: +886-2-23568810
Received: June 24, 2014
Revised: September 22, 2014
Accepted: October 1, 2014
Published online: December 9, 2014
Revised: September 22, 2014
Accepted: October 1, 2014
Published online: December 9, 2014
Core Tip
Core tip: Management of hepatitis C virus (HCV) recurrence after liver transplantation used to be a bothering issue due mostly to the interferon-based therapy. Current available data from treatment of chronic HCV infection shows promising results of interferon-free, or even ribavirin-free, pan-genotypic, all oral medications will soon reform the treatment of HCV recurrence after liver transplantation.